GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lin BioScience Inc (ROCO:6696) » Definitions » Debt-to-Revenue

Lin BioScience (ROCO:6696) Debt-to-Revenue : N/A (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Lin BioScience Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Lin BioScience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$13.48 Mil. Lin BioScience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$36.51 Mil. Lin BioScience's annualized Revenue for the quarter that ended in Jun. 2023 was NT$0.00 Mil.


Lin BioScience Debt-to-Revenue Historical Data

The historical data trend for Lin BioScience's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lin BioScience Debt-to-Revenue Chart

Lin BioScience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A N/A N/A N/A

Lin BioScience Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Lin BioScience's Debt-to-Revenue

For the Biotechnology subindustry, Lin BioScience's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lin BioScience's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lin BioScience's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lin BioScience's Debt-to-Revenue falls into.



Lin BioScience Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Lin BioScience's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(13.847 + 29.026) / N/A
=N/A

Lin BioScience's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(13.484 + 36.51) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.


Lin BioScience Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lin BioScience's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lin BioScience (ROCO:6696) Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao East Road, 12th Floor, No. 68, Section 5, Xinyi District, Taipei City, TWN, 110
Lin BioScience Inc is a drug development company. It specializes in therapies for diseases with unmet medical needs. Its novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology, cardiovascular, and metabolic disease.

Lin BioScience (ROCO:6696) Headlines

No Headlines